Skip to main content
. Author manuscript; available in PMC: 2020 May 11.
Published in final edited form as: ACS Appl Mater Interfaces. 2019 Mar 21;11(13):12342–12356. doi: 10.1021/acsami.9b02408

Figure 8.

Figure 8.

In vivo evaluation of acute toxicity of encapsulated drugs and carrier. (a) Plasma clinical chemistry markers of liver and kidney function and (b) Hematology toxicity parameters from healthy, tumor-free mice 96 hours after a single dose of PBS (control), E MPMs (310 mg/kg poloxamers), or TB MPMs (1.3 mg/kg tal, 1.23 mg/kg bup). (c) Plasma clinical chemistry markers of chronic toxicity of encapsulated drugs and carrier monitoring liver (ALT and AST) and kidney (BUN function.) * denotes statistically significant difference compared to PBS control (p < 0.05).